MedTrace Logo

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NCT03343652 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-05-28

No results posted yet for this study

Summary

A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.

Conditions

  • Hodgkin's Lymphoma

Interventions

DRUG

Nivolumab

3 mg/kg IV infusion on day 1,14 up to 3 cycles

DRUG

Bendamustine Hydrochloride

90 mg/kg IV infusion on day 1 up to 3 cycles

Sponsors & Collaborators

  • St. Petersburg State Pavlov Medical University

    lead OTHER

Principal Investigators

  • Boris V Afanasyev, PhD · First Pavlov State Medical University of St. Petersburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-27
Primary Completion
2019-03-27
Completion
2020-03-27

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03343652 on ClinicalTrials.gov